Nadir neutrophil counts in patients treated for breast cancer with doxorubicin and cyclophosphamide

East African Medical Journal

Volumn 78, Issue 7, 2001, Pages 370-372

  Othieno Abinya, N A ^a   Nyabola, L O ^a   Nyong'o, A O ^b   Baraza, R ^b  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b Nairobi Hospital   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; ARTICLE; BLOOD; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG ADMINISTRATION; FEMALE; HUMAN; LEUKOCYTE COUNT; MIDDLE AGED; NEUTROPENIA; NEUTROPHIL; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; RETROSPECTIVE STUDIES;

EID: 0035411852     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: 10.4314/eamj.v78i7.9011     Document Type: Article

References (14)

1. Marschner N., Kreienberg R. and Sauchon R. et al. Evaluation of the importance and relevance of dose intensity using metastatic breast cancer. Interim analysis of a prospective randomized trial. Semin. Oncol. 1994; 21: 10-16.
2. Cunnings F., Gelman R. and Horton J. Comparison of CAF Vs CMFVP in metastatic breast cancer: Analysis of prognostic factors. J. Clin. Oncol. 1985; 3:932-40.
3. Smalley R., Lefante J. and Bertolucci A. et al. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate and 5-fluorouacil, vincristine and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res. Treat. 1983; 3: 209-20.
4. Van Hoff, D.D., Clark G.M. and Weiss W.R., et al. Use of in vitro dose response effects to select antineoplastics for high dose or regional administration regimens. J. Clin. Oncol. 1986; 4:1827-1834.
5. Skipper H. Data and analyses having to do with the influence of dose intensity and duration of treatment (single drugs and combinations) on lethal toxicity and therapeutic response of experimental neoplasms. Southern Research Institute, Booklets 13 1986, and 2-13 1987.
6. Wood W.C., Budman D.R. and Korzum A.M., et al. Dose sand dose intensity of adjuvant chemotherapy for stage II node positive breast carcinoma. N. Engl. J. Med. 1994; 330: 1523-1529.
7. Skipper H.E. Dose-intensity versus total dose of chemotherapy. An experimental basis. In: DeVita VT, Hellman S, Rosenberg SA (Eds). Important Advances in Oncology. JB Lippincott, Philadelphia, 1990; pp43-64.
8. Hryniuk W. and Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 1984; 2:1281-1288.
9. Dimitrov N., Andersen S. and Fisher B, et al. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): findings from NSABP B-22. Proc. Amer. Soc. Clin. Oncol. 1994; 13: 64 (Abstr 58).
10. Fisher B., Anderson S. and Wickerham D.L., et al. Increased intensification and total dose of cyclophosphamide in a doxorubicincyclophosphamide.regimen for the treatment of primary breast, cancer: Findings from the, National Surgical Adjuvant Breast and Bowel Project B-22. J. Clin. Oncol. 1997; 15:1858-1869.
11. Bonneterre J., Roche' H. and Bremond A. et al. A randomized trial of adjuvant chemotherapy with FEC 50 Vs FEC 100 for node-positive operable breast cancer early report. Proc. Amer. Soc. Clin. Oncol. 1996; 15:104 (Abstr 82).
12. Fisher B., Anderson S. and DeCellis A. et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel project B25. J. Clin. Oncol. 1999; 17-3374-3388.
13. Jones S.E., Khandelwal P. and McIntrye K. et al. Randomized, double-blind, placebo-controlled trial to evaluate the haematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. J. Clin. Oncol. 1999; 17: 3025-3032.
14. Anonymous American Society of Clinical Oncology Outcomes Working Group (core members): Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J. Clin Oncol. 1995; 14: 671-679.